Minocyclin voor de preventie en behandeling van CVA!!
Below another article[as this is long and technical ] I just copy the conclusion [and include the link] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651660/
In summary,minocycline has long been used as an antibiotic for acne vulgaris, perioral disease and cutaneous sarcoidosis, and it is currently used for the treatment of inflammatory diseases such as rheumatoid arthritis. However, minocycline has now been demonstrated to have anti-inflammatory, immunomodulatory and neuroprotective effects. Various studies in animal models and some clinical trials have confirmed the beneficial effects and safety of minocycline, alone or combined with other drugs, as a promising therapeutic for diseases with an inflammatory background. Multiple mechanisms of action have been proposed for minocycline, which stands out as a drug affecting multiple targets. Its antioxidant properties, calcium chelation and ability to inhibit pro-inflammatory enzymes such as iNOS or MMPs may have prominent roles in its beneficial effects in most of the diseases considered in this review. However, other tetracyclines, especially doxycycline, have been reported to share some of these properties, yet have not exhibited a similar efficacy in the same models. Therefore, it seems that it is minocycline's multiple targets that makes it such an outstanding drug among the tetracyclines. In addition, minocycline has been shown to display several attractive advantages that deserve our attention: it is generally considered a safe drug in humans, with a known side-effect profile; it is relatively inexpensive, which makes it suitable for long-term use in these diseases; and, lastly, it is established as an oral therapy, being well absorbed (95–100%) and reaching most of the compartments of the body, including the CNS. Although a better understanding of the mechanisms involved in the action of minocycline in vivo is required before its therapeutic potential can be accurately assessed, the encouraging results and attractive merits of this antibiotic indicate that it will have potential as a therapeutic approach for treating many of the diseases described in this review.
This work was supported by the Spanish Ministry of Science and Innovation (SAF2011-29648), with funds from the European Union and Junta de Andalucia (CTS 164). CIBER-EHD is founded by Instituto de Salud Carlos III. N. Garrido-Mesa is a predoctoral fellow of Spanish Ministry of Education and Science.